Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients
NEW YORK, NY / ACCESSWIRE / May 27, 2021 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor...
Cellbxhealth PLC Announces Holding(s) in Company